NCT03027102View on ClinicalTrials.gov

Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

August 15, 2017

Primary Completion Date

December 10, 2024

Study Completion Date

December 10, 2024

Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL

DNT cells

DNT cells will be expanded (increased in numbers) in the laboratory, in order to enhance their tumour destroying potential before infusion into AML patients.

Trial Locations (1)

M5G2M9

Princess Margaret Cancer Centre, Toronto

Sponsors

Collaborators (1)

Ozmosis Research Inc.
All Listed Sponsors
collaborator

Ozmosis Research Inc.

INDUSTRY

lead

University Health Network, Toronto

OTHER